WBI Investments’s Gilead Sciences GILD Stock Holding History

WBI Investments’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,270	Closed	-$35K	–	245
2014 Q4	$35K	Buy	+1,270	New	+$131K	﹤0.01%	178

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

WBI Investments's GILD Position: Q1 2026 in Review

WBI Investments sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 5,181 shares — an estimated $636K sold.

WBI Investments first reported a position in GILD in Q4 2014 and held it in 20 quarters. The position peaked at $12.8M in Q2 2019. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

WBI Investments reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
WBI Investments sold 5,181 Gilead Sciences shares in Q1 2026, an estimated $636K.
WBI Investments first reported a position in Gilead Sciences in Q4 2014 and held it in 20 quarters.
WBI Investments's Gilead Sciences position peaked at $12.8M in Q2 2019.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on WBI Investments's 13F filing for Q1 2026, filed 11 May 2026.